22 Problems Solved in 2022? Wendover Confuses Scientific Breakthroughs With Solutions

Wendover Productions' 22 Problems Solved in 2022 has a worthy ambition: remind viewers that humanity makes progress even during difficult years. Unfortunately, its definition of a solved problem is so generous that scientific experiments, unfinished clinical trials, regulatory approvals and actual achievements become interchangeable.

That is not a small editorial distinction. A spacecraft that successfully changes an asteroid's orbit has demonstrated a working capability. A chemical reaction in a laboratory has not cleaned a city's drinking water. A vaccine entering clinical trials has not protected a single patient through an approved vaccination programme.

The narrator occasionally acknowledges these distinctions. The malaria vaccines, for example, still needed larger trials, and fusion remained far from commercial application. Yet all these developments appear under the same headline: problems solved.

I examined the evidence behind several of the video's most consequential examples. The results expose one outright policy misstatement and a recurring failure to distinguish scientific progress from practical outcomes.

The Kigali Amendment did not eliminate HFCs

The video makes an unusually clear factual error when discussing the United States joining the Kigali Amendment.

It states that the agreement would:

"phase out 100% of HFCs"

It then tells viewers that manufacturers in the United States and most of the rest of the world would not be able to use these chemicals at all by 2050.

That is not what the agreement requires.

The United States ratified the Kigali Amendment on October 31, 2022. It established an international framework for gradually reducing hydrofluorocarbon production and consumption, not eliminating every permitted use.

The distinction is substantial. Under the American Innovation and Manufacturing Act, the United States is required to reduce HFC production and consumption by 85% against historical baseline levels by 2036.

The EPA's actual allowance schedule leaves production and consumption at 15% of baseline levels from 2036 onward.

Source: US Environmental Protection Agency — HFC Phasedown Schedule.

This is still an important climate achievement. HFCs are powerful greenhouse gases, and reducing their use has substantial environmental benefits.

But a phasedown is not a complete phaseout. A policy that deliberately retains allowances cannot honestly be described as a commitment to eliminate all HFC use.

The video did not need to exaggerate the agreement. The real policy was already worth celebrating.

Nuclear fusion achieved ignition, not usable energy production

The December 2022 fusion announcement was genuinely historic.

Scientists at Lawrence Livermore National Laboratory produced 3.15 megajoules of fusion energy after delivering 2.05 megajoules of laser energy to a fuel target.

For the first time, a controlled fusion experiment achieved a positive energy gain at the target.

The video accurately identifies this as a major scientific milestone. It also acknowledges that the reaction lasted only a fraction of a second.

But there is another number that fundamentally changes how the achievement should be understood.

The laser system required approximately 300 megajoules of electricity from the power grid to generate the 2.05-megajoule laser pulse.

That means the experiment produced 3.15 megajoules of fusion energy while drawing roughly 300 megajoules of electricity for its laser system.

The fusion output was approximately 1% of that electrical input.

This is the difference between target gain and actual energy production.

The distinction was explicitly discussed by Lawrence Livermore National Laboratory director Kim Budil in a December 2022 technical discussion reported by Optics & Photonics News.

Optics & Photonics News — Ignition Accomplished, NIF Looks to the Future.

The facility also had significant practical limitations. It could fire approximately once a day, and producing the fuel capsules required extensive preparation. Its primary mission was nuclear weapons research, not electricity generation.

The laboratory itself describes ignition experiments as advancing the science towards the eventual use of fusion as an energy source.

Lawrence Livermore National Laboratory — Fusion FAQs.

None of this diminishes the scientific achievement. It does, however, make the distinction between proving a reaction possible and solving the world's energy problem unavoidable.

A laboratory has demonstrated ignition. Humanity has not demonstrated a commercially useful fusion power station.

Those are two very different accomplishments.

The PFAS breakthrough was not a solution for contaminated drinking water

The video's discussion of forever chemicals is another example of a promising discovery being presented with more practical reach than the research had established.

In August 2022, researchers led by Brittany Trang published a study in Science demonstrating a chemical process for breaking down certain persistent PFAS compounds.

The method used dimethyl sulfoxide (DMSO), sodium hydroxide and heat.

The research was important. It demonstrated that selected chemicals previously considered extremely difficult to destroy could be broken down into fluoride ions and smaller carbon-containing products.

But the study had a specific scope.

It successfully tested ten perfluoroalkyl carboxylic acids and perfluoroalkyl ether carboxylic acids, including PFOA and GenX.

The US Environmental Protection Agency has identified more than 12,000 PFAS compounds.

Northwestern University, which reported on the research, even used the heading:

"Ten down, 11,990 to go"

Northwestern University — Forever Chemicals Destroyed by Simple New Method.

The researchers had not demonstrated that the process worked across the entire PFAS family.

There was another important limitation: the process required concentrated chemicals. It was not a method for simply pouring contaminated drinking water into a treatment system and eliminating every PFAS compound.

Science News explained that the process might eventually be useful in wastewater treatment after pollutants had first been filtered out and concentrated.

Science News — Common, Cheap Ingredients Can Break Down Some Forever Chemicals.

That is a promising research direction, not an operational municipal treatment solution.

The video connects the discovery to more than 2,000 American cities with PFAS contamination concerns. But the study did not demonstrate that those cities could use the process to make their water safe.

A laboratory breakthrough deserves attention. Communities dealing with contaminated drinking water need something considerably more developed.

Authorizing dam removal is not restoring a river

The Lower Klamath River project provides another useful distinction.

On November 17, 2022, the Federal Energy Regulatory Commission authorized the surrender of the project's hydroelectric licence, subject to conditions requiring the decommissioning of four dams.

This was a major regulatory milestone after approximately two decades of efforts to restore the river.

But the dams were not removed in 2022.

The first dam, Copco No. 2, was removed in November 2023. The remaining three were removed in October 2024.

The California governor's office confirmed completion of the dam-removal work on October 2, 2024.

California Governor — Klamath River Dams Fully Removed Ahead of Schedule.

The project reopened more than 400 miles of historical habitat for salmon and other migratory fish. Restoration of approximately 2,200 acres of formerly submerged land, however, continued after the dams were gone.

The original FERC decision can also be examined in the Government Accountability Office's legal review.

GAO — Federal Energy Regulatory Commission and the Lower Klamath Project, May 8, 2024.

To be fair, Wendover correctly described the 2022 development as authorization for demolition and expressed hope that salmon would return.

The problem is the classification.

A regulatory decision can remove an obstacle to solving a problem. It does not mean the physical work has been completed, much less that the ecosystem has recovered.

In this case, the project eventually delivered a remarkable result. But the result belongs to 2024, not 2022.

The vaccine stories were forecasts, not completed medical solutions

The malaria and Lyme disease examples illustrate why clinical research must be separated from actual medical availability.

The video discusses the Oxford malaria vaccine candidate, which had demonstrated promising results in clinical trials. It also identifies an Indian manufacturer preparing to produce more than 100 million doses.

The narrator does acknowledge that larger trials were still required.

That qualification matters.

The World Health Organization did not recommend the R21/Matrix-M malaria vaccine until October 2, 2023.

WHO — Recommendation of the R21/Matrix-M Malaria Vaccine.

The vaccine subsequently became a genuine public-health achievement, and its manufacturer established production capacity of 100 million doses annually.

The optimism was justified. But the approval came the following year.

The Lyme disease vaccine story demonstrates the uncertainty even more clearly.

In August 2022, Pfizer and Valneva began a Phase 3 clinical trial of VLA15 involving approximately 6,000 participants.

The video presented this as a potentially imminent solution to a disease that had lacked an available human vaccine.

Yet the candidate remained investigational for years.

On March 23, 2026, Pfizer and Valneva announced Phase 3 results showing 73.2% efficacy in the primary analysis. However, the trial failed its predefined primary statistical criterion because the lower bound of the confidence interval was 15.8%, below the required 20%.

A second prespecified analysis showed 74.8% efficacy and met the statistical threshold. The companies expressed confidence and planned regulatory submissions.

Pfizer nevertheless confirmed that no Lyme disease vaccine was currently available.

Pfizer — Phase 3 VALOR Lyme Vaccine Results, March 23, 2026.

Four years after the original video, the vaccine still had not become an approved product.

That is precisely why clinical trial results should not be confused with completed medical solutions.

The underlying editorial problem

These examples are not isolated mistakes. They expose a weakness in the video's central organizing idea.

Consider the different kinds of developments included in its 22-item list:

• NASA demonstrated a working asteroid-deflection technique.
• Ethereum completed its transition to proof-of-stake.
• The United States committed funding to abandoned-well remediation.
• The Klamath River project received authorization for dam removal.
• PFAS researchers demonstrated a laboratory chemical reaction.
• Vaccine developers advanced candidates into clinical trials.
• Intel announced a deepfake detection product with a company-reported accuracy figure.

All these developments have value. But they represent different stages of progress.

An enacted agreement is not the same as a completed programme. A scientific discovery is not the same as a commercially deployable technology. A clinical trial is not the same as an approved vaccine.

The video occasionally explains these distinctions within individual segments, but its overall presentation encourages viewers to treat them as equivalent victories.

That is particularly problematic when the subject is public health, environmental remediation or future energy production. People need to know whether a solution exists, whether it works outside a laboratory, whether it has been approved, and whether it has actually reached the people who need it.

Without those distinctions, a list of achievements becomes a list of expectations.

Verdict: Progress deserves celebration. Completion requires proof.

Wendover's video contains genuine achievements, important scientific discoveries and worthwhile policy developments.

Its central weakness is not that it celebrates progress. It is that it repeatedly blurs the line between a problem being addressed and a problem being solved.

The Kigali Amendment is a real climate achievement, but it does not eliminate all HFC use. Fusion ignition is a genuine scientific milestone, but it does not produce net electricity. The PFAS research is promising, but it is not a municipal drinking-water solution. The Klamath authorization was important, but the dams remained in place until 2023–2024.

The malaria vaccine eventually became a WHO-recommended product. The Lyme vaccine remained under development years after the episode.

These distinctions are not technicalities. They are the substance of the stories.

A reader should not have to discover years later that a celebrated solution was still waiting for approval, funding, engineering, construction or implementation.

Human progress is real. But announcing progress as completion is a disservice to the people still waiting for the problem to be solved.

References

1. 22 Problems Solved in 2022 — Wendover Productions, 2022. Original video. The primary work under examination, including its claims about scientific breakthroughs, policies and unfinished research.
2. Frequent Questions on the Phasedown of Hydrofluorocarbons — US Environmental Protection Agency. Direct source. Establishes the actual American HFC reduction schedule and the continuing 15% production and consumption allowance.
3. Ignition Accomplished, NIF Looks to the Future — Optics & Photonics News, December 2022. Direct source. Documents the 300-megajoule electricity requirement, laser limitations and distance between laboratory ignition and commercial fusion.
4. FAQs: Extreme Light, Matter, and Fusion — Lawrence Livermore National Laboratory. Direct source. Provides the official definition of fusion ignition and the measured energy delivered to the target.
5. Low-temperature Mineralization of Perfluorocarboxylic Acids — Brittany Trang et al., Science, August 19, 2022. Research paper. The original scientific study establishing the chemical process and its specific scope.
6. Common, Cheap Ingredients Can Break Down Some Forever Chemicals — Science News, August 18, 2022. Direct source. Explains the laboratory limitations, concentration requirements and possible future wastewater applications.
7. Federal Energy Regulatory Commission — Lower Klamath Project License Decision — US Government Accountability Office, May 8, 2024. Direct source. Establishes that the November 2022 decision authorized dam decommissioning subject to conditions.
8. Klamath River Dams Fully Removed Ahead of Schedule — Governor of California, October 2, 2024. Direct source. Confirms when the four-dam removal project was actually completed and identifies restoration work that continued afterward.
9. WHO Recommends R21/Matrix-M Vaccine for Malaria Prevention — World Health Organization, October 2, 2023. Direct source. Establishes the subsequent date of the vaccine's WHO recommendation.
10. Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial — Pfizer, March 23, 2026. Direct source. Provides the latest trial results, the missed primary statistical criterion and the companies' planned regulatory submissions.

Tighten the opening thesisSeparate factual errors from fair criticism